USA News Group – Bitcoin (BTC) or Dogecoin (DOGE)? Which cryptocurrency will prevail and be embraced as the “currency of the internet and the people”? This question recently caused a brief but intense spat between a pair of Silicon Valley giants: Jack Dorsey, the co-founder of Twitter Inc. (NYSE:TWTR) and CEO of Block, Inc. (NYSE:SQ), and Vlad Tenev, CEO of Robinhood Markets, Inc. (NASDAQ:HOOD). Dogecoin has surged over the last two years in popularity and mindshare, to knock at the door of #2 cryptocurrency Ethereum. Soon after SpaceX CEO Elon Musk began making a serious play to acquire Twitter, DOGE prices shifted, causing Forbes to infer Dogecoin as a ‘Proxy for Twitter Stock’. As the debate rages onward, cryptomining specialists have benefitted such as Neptune Digital Assets Corp. (TSXV:NDA) (OTC:NPPTF), and Hello Pal International Inc. (CSE:HP) (OTC:HLLPF) which recently combine its crypto mining capabilities with its successful video livestreaming and matching businesses.
The newly launched DogeChat and DoggeChat apps from Hello Pal International Inc. (CSE:HP) (OTC:HLLPF) are set to allow users to match and/or video chat with other individual users from across the globe. When a connection is made, 1-on-1 video calls will generate revenues on a per-minute basis, paid for by the call’s initiator to the call’s receiver—now with the option to pay in crypto, which Hello Pal also is in the business of mining.
“We expect these apps to be very synergistic to our current livestreaming and crypto-mining operations,” said KL Wong, Founder and Chairman of Hello Pal. “They will not only bring into our existing ecosystem new users from different markets, but also allow us to start implementing our goal to make the use of cryptocurrency more widespread in the world, starting with our users.”
Where DogeChat payments will be made in DOGE and other cryptocurrencies, DoggeChat payments will be in fiat currencies made through Apple Pay and Google Pay. First to launch will be DoggeChat, before DogeChat is launched at a later date, using the same user pool. However,
regular users of DoggeChat will be incentivized in various ways to switch to DogeChat.
Hello Pal made history back in May 2021 by becoming the market’s first listed company focused on DOGE mining. Reaction to the announcement was swift, causing a surge in traffic so heavy it temporarily caused a website outage.
Both the DoggeChat and DogeChat launches represent Hello Pal’s market expansion into the burgeoning 1-on-1 video chatting space, as well as its foray into the North American market.
More significantly, it also represents their plan to start incorporating cryptocurrency payments into their social and livestreaming businesses.
Meanwhile, in terms of revenues from cryptocurrency mining, Hello Pal and Neptune Digital Assets Corp. (TSXV:NDA) (OTC:NPPTF) have similar market caps and both recently reported strong revenues from their operations.
Back in FebruaryHello Pal, was still transitioning its mining operations out of China, while increasing its mining assets and improving upon its crypto-mining operations infrastructure.
“Our livestreaming operations continue to deliver strong operating results as we continue to diversify outside of China,” said KL Wong. “With our focus on cryptocurrency mining operations, we anticipate that revenue and profit will continue in an upward trend.”
Whereas Hello Pal focuses its mining on DOGE, Neptune Digital Assets focuses more on BTC.
During Q1 2022, Neptune Digital Assets set a fiscal quarter record with C$13 million in comprehensive income, derived from not only mining, but staking and DeFi earnings and crypto fund investment as well.
“We hope to see the general crypto space grow as we move forward into 2022 and our Bitcoin mining, staking, and DeFi earnings to increase accordingly as we grow those arms of the business,” stated Cale Moodie, Neptune CEO. “We anticipate another 53 petahash of mining capacity to come online in Q2 thus growing our Bitcoin earnings. We are staying true to our diversified model and will continue to manage our risk while maximizing our earnings across the board.”
Which brings things back to the feud on Twitter Inc. (NYSE:TWTR) between Jack Dorsey CEO of Block, Inc. (NYSE:SQ), and Vlad Tenev, CEO of Robinhood Markets, Inc. (NASDAQ:HOOD).
Tenev began the conversation, positing in a Tweet: “Can #Doge truly be the future currency of the internet and the people? As we added the ability to send/receive DOGE on Robinhood, I’ve been thinking about what that would take.”
He went on to claim that Dogecoin could outperform Visa with respect to transaction speedsd, and that the crypto coin’s transaction speeds would eventually surpass the credit card giant’s current 65,000 transactions per second (TPS) capabilities.
“Doge would need to be able to significantly outperform Visa, which entails increasing throughput by at least 10000x,” wrote Tenev.
While there was plenty of support for Tenev’s musings, others on Twitter began to push back, including the social media platform’s co-founder and former CEO, Jack Dorsey, with pointed barbs that reflected some of the audience’s skepticism due to Robinhood’s more recent dependence on DOGE for its revenue and profits.
Dorsey responded to Tenev’s final tweet with a snarky, “u thirsty?”, to which Tenev fired back with “U mad?”
Not leaving it alone, Dorsey replied, “nah I’m good I don’t use Robinhood.”
Tenev cleverly got the final word, capitalizing on an opportunity for Robinhood plug, replying “you would pay less for your bitcoin if you did!”
Twitter Inc. (NYSE:TWTR) itself isn’t playing a spectator in the cryptocurrency scene, by working with online payments firm Stripe to become the first company to integrate a new payment method that makes payouts in crypto through the stablecoin USDC. Beginning right away, Twitter will let a certain number of creators receive their earnings from its paid Ticketed Spaces and Super Follows features in USDC.
Block Inc. (NYSE:SQ) CEO Dorsey has gone all in on Bitcoin, with his departure from Twitter leading Bloomberg’s Businessweek to claim his intention is become Bitcoin’s “Spiritual Leader.”
His company is set to work with cryptocurrency storage company Blockstream to construct a solar-powered BTC mining facility in Texas. The 3.8-megawatt (MW) facility will be outfitted with Tesla’s solar photovoltaic cell array and a 12 MWh Megapack.
As some were criticizing Tenev for being biased in his support of DOGE, the seemingly critical anti-Dogecoin and anti-Ethereum statements of Dorsey while being hyper-focused on BTC could also be seen as biased.
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Hello Pal International Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Hello Pal International Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Hello Pal International Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Hello Pal International Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Rare Diseases and Orphan Drugs shows that much of what we now know about common diseases has been achieved by studying rare diseases. It proposes that future advances in the prevention, diagnosis, and treatment of common diseases will come as a consequence of our accelerating progress in the field of rare diseases.
Understanding the complex steps in the development of common diseases, such as cancer, cardiovascular disease, and metabolic diseases, has proven a difficult problem. Rare diseases, however, are often caused by aberrations of a single gene. In rare diseases, we may study how specific genetic defects can trigger a series of events that lead to the expression of a particular disease. Often, the disease process manifested in a certain rare disease is strikingly similar to the disease process observed in a common disease.
This work ties the lessons learned about rare diseases to our understanding of common ones. Chapters covering the number of common diseases are minimized, while rare diseases are introduced as single diseases or as members of diseases classes. After reading this book, readers will appreciate how further research into the rare diseases may lead to new methods for preventing, diagnosing, and treating all diseases, rare or common.
For more information on this sector, please enter your email address in the box provided on this page and we will be happy to send you information as it becomes available to us
One of the best kept secrets among most seasoned biopharma investors is the lucrative and enticing potential for treating rare diseases with orphan drugs.
PAY ATTENTION: We’ve identified a rare-disease, orphan-drug company declared by multiple analysts as a STRONG BUY* with price targets in excess of 350%—and that company is Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX). – This company is extremely undervalued, analysts agree as you will see below, and we personally think it is a huge bargain at this price point with major upside potential in the very near future.
Market research firm EvaluatePharma projects that worldwide orphan-drug sales will DOUBLE by 2026 to hit US$268 billion[1], and Prophecy Market Insights projects it will be more than DOUBLE of that, hitting US$547.5 billion by 2030, growing at a RAPID 13.1% CAGR.[2]
What is an Orphan Drug?
Orphan drugs are medicines developed to help treat, prevent or diagnose rare “orphan” diseases, which are conditions that each affect fewer than 200,000 people in the U.S. Today, about 600 orphan drugs are approved by the U.S. Food and Drug Administration (FDA) to treat these difficult and rare diseases. In order to spur pharmaceutical companies to develop more Orphan Drugs, Congress passed the Orphan Drug Act in 1983. This law encourages drug makers to research and manufacture orphan drugs by giving them tax incentives, subsidies for clinical research. This program has been very successful and very lucrative.
Analysts are bullish on QNRX and the sector as you can see by the above average price target of $6.50, with a low target of $5.00 and and a high target of $8.00.
So, let’s look at some of the major factors behind this rare disease market that has been incentivized from what was once a barren land into totally fertile ground.
Roughly 30 million Americans suffer from 7,000 or so rare diseases.[8]
And to address these patients, the US FDA funds research in rare diseases through programs like the Orphan Products Grants Program, by implementing the Orphan Drug Act, and reviewing and granting designations to Rare Disease Drugs, Rare Pediatric Diseases, and Devices. To sweeten the pot, the FDA also offers seven years for Orphan Drug Exclusivity (ODE), giving two whole years more of market exclusivity than New Chemical Entity Exclusivity (NCE).[9]
Because of this, biopharma companies are VERY attracted to the orphan-drug market. After decades since the passage of the Orphan Drug Act, the FDA has given orphan status to over 500 drugs[10], while the EU has given orphan designation to over 2,200 medicines.[11]
As of 2020, the FDA had approved drugs and biologics for over 800 rare disease indications.[12] Rare-disease drugmakers are BIG business, and even mean a lot to BIG Pharma. In 2021, AstraZeneca both acquired rare disease drug makers (Alexion) for US$39 billion[13], and agreed to pay up to $3.6 billion for the rights to a promising drug for another rare disease.[14]
UCB recently bought rare disease Zogenix for up to US$1.9 billion,[15] Italian pharma group Recordati closed out 2021 by signing an agreement to buy UK-based EUSA Pharma for an enterprised value of nearly US$850 million.[16]
“Orphans are wicked hot.”
– Dr. Tim Coté, Former FDA official, and CEO of Only Orphans Cote LLC [17]
30-Second Intro: A SpecialSpecialty Pharma Co.
Tightly-held share structure, and currently valued at less than $11.5M
Trading at less than $1.35.
Multiple analysts have given QNRX a ‘BUY’ or ‘STRONG BUY’ Rating.
Publicly shared analyst price targets avg $6.50 per share and as high as $8 per share.[18]
Rare and Orphan Disease Focused specialty pharmaceutical company.
Innovative Pipeline with three products targeting a broad number of rare and orphan diseases, including Rare Pediatric Designations.
Plans in placeto establish a sales infrastructure to commercialize its products in both the USA and Europe.
Targeting US/EU Approvals in 2024, 2025, and 2026.
Established Strategic licensing partnerships for entry into multiple markets.
Strong Key Opinion Leader (KOL) support.
Experienced Management Team.
Capital Structure Statistics Total Shares Outstanding — 8,350,000 Average Volume — 2.47 Million Market Cap — $11.2 Million Institution Ownership — 10.57%
QUICK RUNDOWN: THE PIPELINE
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) is focused on developing innovative treatments for rare and orphan diseases, and has a pipeline that comprises three unique products (including QRX003, QRX004, and QRX006) that collectively have the potential to target a broad number of indications.
**FLAGSHIP** QRX003: Netherton Syndrome
QRX003is under development as a potential therapy for the treatment of Netherton Syndrome (NS)— a rare, hereditary skin disorder leading to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma and eczema.
Patients also often suffer from severe dehydration, chronic skin inflammation and stunted growth.
People with Netherton Syndrome have too few layers of their outer skin (stratum corneum) so the skin does not perform its primary function as a protective barrier.
Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.
QRX003 is a once-daily topical lotion that offers a combination of a broad-spectrum serine protease inhibitor, and is formulated with Quoin Pharmaceuticals’ (NASDAQ:QNRX) proprietary Invisicare® technology.
When applied daily to the skin, the active ingredient in QRX003 leads to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier, while also acting as a potent anti-inflammatory and antioxidant.
QRX004is also a topical lotion made with Quoin Pharmaceuticals’ (NASDAQ:QNRX) proprietary Invisicare® technology, initially under development as a potential treatment for a group of rare and genetic skin disorders, in which the skin is so trauma or friction, which can have devastating results, cause severe pain, blistering, scarring, infection and immobility.
Known as Recessive Dystrophic Epidermolysis Bullosa (RDEB), it’s diagnosed at infancy and accompanied by a high mortality rate – 76% do not live beyond their 30s.
The cost of bandaging alone can exceed $10,000 per month.
Quoin Pharmaceuticals’ (NASDAQ:QNRX) QRX004is designed for the creation of robust and sustained type VII collagen, and for improved wound closure, reduced blistering and stronger skin.
QRX006: Undisclosed Rare Skin Disease
QRX006is another a topical lotion that Quoin Pharmaceuticals (NASDAQ:QNRX) is developing for an, as of yet, undisclosed rare skin disease.
It contains two separate active ingredients and is designed to be applied directly to the affected site over a prescribed period.
Currently available treatment involves the daily systemic administration (oral and IV) of the same two active ingredients that are in QRX006 over a period of several weeks.
This treatment is both cumbersome and costly for patients and healthcare providers and can lead to significant unpleasant side effects, often resulting in patients discontinuing treatment.
QRX006 is designed to reduce the side effects associated with systemic treatment and enable patients to apply the product directly themselves without the need for daily visits to a hospital or clinic.
Quoin Pharmaceuticals (NASDAQ:QNRX) applied for a patent for QRX006 in mid-2021.
AT THIS POINT we have identified a publicly-traded company with multiple assets in the pipeline and in planning stages of establishing sales infrastructure for the USA and Europe… and that company is Quoin Pharmaceuticals (NASDAQ:QNRX)
Strategic Partnerships
Quoin Pharmaceuticals (NASDAQ:QNRX) has established partnerships with other companies and advocacy organizations.
FIRST was established to help individuals and families affected by ichthyosis.
The organization educates, inspires, and connects families and individuals affected by Ichthyosis and related skin types. Services include biennial national family conferences, regional meetings, a regional support network, publications, advocacy and a research program.
Quoin Pharmaceuticals (NASDAQ:QNRX) has in-licensed a bi-functional biologic from QUT for the treatment of Netherton Syndrome.
Quoin Pharmaceuticals (NASDAQ:QNRX) has entered into a licensing and distribution agreement with GenPharm for the Middle East.
AFT is Quoin’s licensing and distribution partner for Australia and New Zealand.
Feature Company:
Quoin Pharmaceuticals Trade Symbol – NASDAQ:QNRX Market Cap – ~$11.3 Million Shares Outstanding: 8.35M
Leaders With Experience
Quoin Pharmaceuticals (NASDAQ:QNRX) is led by a group of seasoned management, board & advisors with particular skill sets and significant wins in the pharmaceutical sector.
Co-Founder, Chairman, CEO & Director Dr. Michael Myers brings more than 30 years of experience in the drug delivery and specialty pharmaceutical sectors. He’s served as CEO of Innocoll, Inc., where he was responsible for taking that company public in 2014, and also served in presidential roles for West Pharmaceutical Services, Fuisz Technologies (Biovai), and executive positions in Flamel Technologies and Elan Corporation. Dr. Myers also serves on the Board of Directors for Sonoran Biosciences as well as on the Advisory Boards for two Penn State startup companies, Cranial Devices and Gradient T.
Co-Founder, COO & Director Denise Carter also has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. Carter and Myers have both worked at Innocoll, Inc., where she served as executive vice president of business development of the drug delivery division. Ms. Carter also held executive positions at Eurand and Fuisz Technologies (Biovail).
Among the members of the Board is Director Dr. Dennis H. Langer, MD, JD, whose spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK, and served as President at Dr. Reddy’s, NA. He’s also served as Director at Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma) and Delcath Systems. He currently serves as a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics.
Before You Go… REMEMBER THESE 5 POINTS
Quoin Pharmaceuticals (NASDAQ:QNRX) and its proprietary Invisicare® technology are well- positioned to succeed in 2022.
Analysts currently covering the company are unanimous in their BUY recommendations.
QNRX is a VERY tightly held stock, with only 8.35M shares outstanding, and 10.57% institutional ownership.
It currently trades at less than $1.30 per share, but has an average price forecast of $6.50, with estimates between $5-$8 for 2022.
Big Pharma is spending BILLIONS to acquire, retain, and develop rare disease/orphan drug treatments.
So putQuoin Pharmaceuticals (NASDAQ:QNRX) on your radar, and do your own research to see why we felt it so necessary to bring it to your attention TODAY.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is NOT a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has not been paid a fee for profiling Quoin Pharmaceuticals on this website or in other market publications, but . There we doo own shares of Quoin Pharmaceuticals which were purchased in the open market, which we plan to sell immediately and will sell in the immediate future. There may also be 3rd parties who may have purchased shares of Quoin Pharmaceuticals, and may liquidate their shares which could have a negative effect on the price of the stock. The simple fact that we own shares of Quoin Pharmaceuticals constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQ, our associates, employees and friends also reserve the right to buy and sell, and will buy and sell shares of Quoin Pharmaceuticals at any time hereafter without any further notice. Let this disclaimer serve as notice that all material disseminated by MIQ has not been approved by Quoin Pharmaceuticals; this is not a paid advertisement, but we own shares of the Quoin Pharmaceuticals which were purchased in the open market that we will sell commencing immediately, and we also reserve the right to buy and sell shares of the company in the open market and we will buy and sell shares in the open market commencing immedaitely.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) – the “Berkshire Hathaway of Tech-Enabled Healthcare” – Could Be the Next Giant Healthtech Conglomerate
When Warren Buffett first bought Berkshire Hathaway in 1962, it was nothing more than a struggling textile mill.
Today, it is a $600+ billion conglomerate juggernaut,[1] owning businesses ranging from insurance and utilities to railroads and chemicals.
Berkshire’s journey from humble mill to giant conglomerate is incredible. Unfortunately,the Berkshire of today is far too huge to generate the kind of returns that can truly change individual investors’ lives.
It has become “just another” blue-chip stock – and one that some think has come in late or missed the boat entirely on many disruptive technologies.
But there’s one fast-growing company that is in a position to have a profound impact on investor returns. It has learned from companies like Berkshire, incorporating what is arguably Berkshire’s greatest strength – its operating structure…
Where the holding company acts like a giant institutional investor, seeking out operating companies to invest in that can generate the highest ROI…
And letting these subsidiaries operate independently with minimal interference, while the holding company does what it does best – efficiently allocating capital.
But this company has learned from Berkshire’s mistakes – and even improved on its operating model.
What’s this company, you may ask? None other than WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF).
WELL firmly understands that technology is the future, and is committed to fully capitalizing on this wave…
Plus, it is only focused on acquiring companies within the multi-trillion-dollar healthcare sector, which allows it to generate powerful value-boosting synergies among its acquisitions (something that Berkshire does not focus on due to its divergent scope of investments).
And its biggest investor? Multi-billionaire Sir Li Ka-Shing – ranked the 43rd richest person in the world with a networth of $34.6 billion[2] and nicknamed “Superman Li” for his business prowess.
That’s why it could be no exaggeration to say that…
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) is the “Berkshire Hathaway of Tech-Enabled Healthcare” – and the Company Could Be on the Cusp of a Major Growth Spurt
Much like Berkshire started in the textile business, WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)began as a humble medical clinic operator.
And in just a few short years, it has grown to become a billion-dollar omni-channel company with 7 different healthcare business lines, including health clinics, electronic medical records (EMR), telehealth, digital apps, billing and cybersecurity…
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)owns 27 primary healthcare clinics in North America – the largest network in BC and the third-largest in Canada…
It operates a multi-national EMR business including its OSCAR Pro EMR asset, which is the third-largest EMR service provider in Canada (a $26.1 billion global market that’s expected to hit $39.4 billion within 5 years[3])…
Its leading Canadian telehealth service conducts thousands of patient visits daily using its software.
All this was done through disciplined and accretive acquisitions, with shareholder dilution always being carefully managed.
And although its stock has shot up by 313% since 2020[4]…
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) Remains Substantially Undervalued Compared to Its Peers…
Even though…
Its EBITDA already turned positive in the fourth quarter of 2020, with a 53% revenue growth for the year…
It’s just completed a major acquisition that would add approximately C$175 million in revenues and C$72 million in EBITDA to its earnings…
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)has 10 signed letters of intent that could add another C$100+ million to its annual revenues by the end of 2021…
And it’s planning a US IPO by the end of the year.
*Share Price and Market cap taken from Yahoo Finance on April 14, 2021
**This revenue figure is inclusive of the company’s recent (completed) acquisition of CRH Medical, estimated to be on a runrate basis based on consensus estimates.
When compared to others in the industry, WELL’s peer group trades at 10x to 20x revenue multiples, while WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)trades at an EV to sales multiple of just 5x.
This means that although the company is far from being a risky early-stage startup company…
It still has plenty of room to grow, particularly as it continues to ramp up its acquisitions…
Which could place WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)in the perfect risk-reward “sweet spot” for investors…
But this window of opportunity may be closing, as analysts expect its valuations to increase to a range more in line with its peers once the US IPO happens.
8 Reasons WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) Could Be the Healthtech Play of the Future
Multi-channel Capability: With healthcare clinics, EMR services, telehealth offerings, digital apps, and more, the company is truly multi-channel, multi-service, and omni-channel in nature – able to offer both in-person and digital solutions to patients, healthcare professionals, and clinics. This allows the company to not only benefit from all aspects of the healthcare industry, but also provides defensive diversification qualities.
Track Record of Accretive Acquisitions: WELL Health(TSX: WELL – OTC: WLYYF)has a solid track record of buying profit-generating companies that can continually add value to its bottom line – all with carefully-controlled shareholder dilution. For instance, due to its acquisition of CRH Health, it is expected to experience 120% accretion to revenue and 800% accretion to EBITDA on a per share basis. However, shareholder dilution was limited to a mere 17%.
Value-Boosting Synergies Within Business Lines: Post-acquisition, the company also has multiple opportunities to add further value to its acquisitions via internal synergies within its business lines. For example, the company is planning to cross-sell its digital services to CRH Health’s network of over 3,000 Gastroenterologist physicians, which are currently generally digitally underserved.
Rapid Acquisition and Growth Strategy: Within the first three months of 2021 alone, WELL Health(TSX: WELL – OTC: WLYYF)has already announced six acquisitions – one of which is a major US player. The company also has another 10 signed letters of intent that could add C$100+ million to annual revenues. Further, recent acquisition CRH Medical is itself a proven M&A player with a track record of 32 acquisitions and over 500 active deal targets.
Strong Investor Base: Multi-billionaire Li Ka-shing is a strategic investor in the company, among other institutional investors such as Manulife, CI Investments, Sentry Investments, Iconiq Capital, Fiera Capital, and the PenderFund Capital. Li Ka-shing and his partner personally led a C$302.5 million equity raise for the CRH Medical acquisition with their own investment of C$100M at an unprecedented 25% premium to market (based on the 5 day VWAP before announcement) – the additional C$202.5M came from the other institutional investors at the same premium.
Well Funded With a Strong Balance Sheet: WELL Health(TSX: WELL – OTC: WLYYF) boasts C$87 million in cash as at end-2020 – with zero debt. Only recently did the company take on some debt as part of the CRH Medical acquisition. However, even said debt facility was obtained at highly cost-effective rates of between 1.5% to 3.25% depending on leverage ratios.
Future US IPO Listing: The company’s targeted US IPO in late 2021 will provide an additional cash infusion that it can use to turbocharge its acquisition strategy. Further, analysts also expect a US listing to push the company’s valuation upwards to a level more in line with its peers. WELL is grossly undervalued when compared against US comps.
Proven Management Team with Skin in the Game: WELL Health’s(TSX: WELL – OTC: WLYYF)management team are all veterans of Tio Networks, a multichannel bill payment processor that was acquired by PayPal for C$304 million in 2017.[13] They’re also all heavily invested in the company, with the CEO personally investing approximately C$6 million in company stock – and never having sold a single share or taken a dollar of cash as salary thus far.
With all these factors in its favor, WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)is…
Well-Positioned to Capitalize on the Massive Digital Transformation Wave Sweeping Through the Healthcare Industry
The health crisis has accelerated digital transformation in all areas, and healthcare is no exception.
For proof of this, look no further than telehealth.
In 2019, research firm Fortune Business Insights[14] estimated the size of the global telehealth market at “only” $61.4 billion…
By 2027, it expects that number to hit $559.5 billion, a compound annual growth rate of over 25%. That’s an astounding growth rate that shows just how big the digital transformation opportunity in healthcare is.
Because although telehealth could soon be worth hundreds of billions, it’s still just one part of the larger digital transformation opportunity…
And WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) is strongly positioned to benefit from all aspects of this opportunity thanks to its multi-pronged approach to healthcare tech.
Beyond that, each new acquisition generates incremental opportunities for its existing subsidiaries, meaning the whole is truly greater than the sum of its parts.
Just like how…
WELL’s (TSX: WELL – OTC: WLYYF) Recent Acquisition of CRH Medical Could Soon Turn the Company into a North American Digital Health Powerhouse
CRH Medical is a major player in the US gastroenterology (GI) market, with 72 GI ambulatory service centers, 411 GI providers, and over 3,200 GI providers trained to use its products and services.
This alone is already enough to generate over C$175 million in annual revenues, with an incredible 26% free cash flow margin.
Yet as investment bank Eight Capital said in a recent research report[15]…
“CRH’s +72 clinic footprint remains digitally underpenetrated, providing a greenfield opportunity for cross-sell. We expect the introduction of a telehealth offering to optimize consumer reach and patient in- and outflow. Plans for the development of a GI-focused app will expand CRH’s reach, increase traffic to clinics, and push product sales.”
In other words, the additional C$175+ million in revenues – not to mention C$72 million in EBITDA and C$45 million in free cash flow – is just the beginning of CRH Medical’s potential…
Because once WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)integrates its digital health offerings with CRH Medical, it could be well on its way toward becoming the next North American digital health powerhouse.
Not to mention that CRH Medical is itself planning to swiftly expand its network and offerings through acquisitions (it has 500 active deal targets in its pipeline)…
Meaning the cross-sell synergies will have a powerful multiplier effect even years down the line.
The best part? All this was done with only a 17% shareholder dilution for Well Health’s (TSX: WELL – OTC: WLYYF)shareholders.
It’s all thanks to the support of the company’s strong investor base, who were all too happy to put in their money at a 25% market premium (investors in this round included every member of its board and most of its management team, including the CEO and CFO of the company)…
Because they realized that the CRH Medical acquisition puts WELL Health in a great position for a US listing…
A powerful catalyst that is widely expected to drive its valuations up toward the ranges offered by its peers.
But while much focus has been (rightfully) given toward the company’s CRH Medical acquisition…
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) Has Been Steadily Conquering the Digital Healthcare Industry, One Acquisition at a Time
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) is a diversified healthtech conglomerate that is rapidly making inroads in all aspects of digital health…
Just look at all of its businesses that it already has:
Like the $26.1 billion EMR market, an industry that is quickly growing as clinics scramble to digitize…
Because EMR is the “enterprise backbone” of a clinic, a system that manages everything from the backend database to the frontend point of sale…
Meaning clinics are unlikely to be able to remain competitive in the modern healthcare market for long without an EMR system.
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) is already the third-largest player in Canada for EMR…
Its main EMR offering – OSCAR Pro – is also open source, giving it greater versatility compared to its competitors. It has been a market share taker in Canada because of its strong interoperability with a large community of third-party app developers.
The company is also quickly adding to its EMR business line with other acquisitions, such as IntraHealth, an enterprise class EMR vendor with customers in Canada, Australia and New Zealand.
Meanwhile, it’s also transitioning clinics owned by newly-acquired subsidiaries over to its EMR platform – showing just how easily the company can generate internal synergies.
Another example is its acquisition of Silicon Valley – and Y Combinator-backed – company Circle Medical.
WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)completed a majority stake investment in Circle Medical in November 2020.
Yet in the past four months, Circle Medical’s revenues have nearly doubled…
This highlights Well Health’s (TSX: WELL – OTC: WLYYF)specialty – strategically allocating capital to undervalued companies that are usually on the cusp of greater growth, which makes the company…
A Fast-Growing, Diversified, and Undervalued Healthtech Play With Multiple Catalysts on the Horizon
Investors looking to invest in the digital transformation that is happening in the trillion-dollar healthcare industry face a common dilemma…
The industry is so vast, with so many different sub-sectors (both B2B and B2C) that they may not even know where to start.
Even if they did know about the various sub-sectors, they would need to invest in many different companies to have a truly holistic and diversified exposure…
Or, they could choose to invest in the large multi-billion dollar health conglomerates – where most of the major returns have already been snatched up years ago by early investors.
WELL Health Technologies Corp. (TSX:WELL) could be the answer to that dilemma…
It offers investors:
Diversified exposure to the entire tech-enabled healthcare market with a single investment…
Strong near-term growth opportunities thanks to multiple catalysts on the horizon – such as its expansion into the US from its CRH Medical acquisition plus its planned US IPO, as well as its 10 pending signed LOIs…
Long-term value from disciplined and accretive acquisitions that also benefit from internal synergies…
All at a price that analysts consider substantially undervalued.
So, instead of spending all that time and effort untangling the complex web that is healthtech, just to find a company that may or may not pan out…
Why not look at a company whose sole specialty is finding undervalued profit-generating companies across the entire healthtech spectrum, and then consolidating and modernizing them to create even more value?
In other words, why not let WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF)do the work for you?
There’s a reason the company was recognized as a TSX Venture 50 company for three years in a row[16]…
Plus, its management team’s track record speaks for itself.
WELL Health Technologies Corp.’s (TSX: WELL – OTC: WLYYF) Has a Management Team Consisting of Nothing but Proven Veterans
Hamed Shahbazi – Chairman & CEO
With over 20 years as a technology-focused operator, Shahbazi has a razor-sharp understanding of the intricacies of identifying opportunities and generating value in the sector. He was the founder of TIO Networks, originally a kiosk solution provider before Shahbazi transitioned it into a multichannel payment solution provider specializing in bill payments and other financial services. As a result, the company was acquired by PayPal in 2017 for C$304 million.
Shahbazi has extensive experience in strategic mergers, acquisitions, and divestitures, both as an operator and board member, with more than a dozen successful transactions. He is also the Lead Independent Director for mediatech company BBTV Corp, as well as the owner and operator of Impactreneur Capital Corp, which has over a dozen investments in leading digital content, ehealth, insurtech, and other technology inspired companies.
Dr. Michael Frankel – Chief Medical Officer
Dr. Frankel has 29 years of experience as a general practitioner in the Lower Mainland, giving him a wealth of experience in the medical industry. But more than just being a doctor, Dr. Frankel is also a healthcare investor and businessman, owning and operating a portfolio of successful primary healthcare facilities. This gives him a deep understanding of what healthcare facilities are lacking and how they can be improved – a crucial piece of WELL Health’s (TSX:WELL) strategy.
Eva Fong, FCCA, CPA, CGA – Chief Financial Officer
As the VP in charge of corporate strategy and M&A at TIO Networks, Fong intimately understands the full lifecycle of M&A transactions, from prospecting to integration and regulatory compliance management.
Her 25 years of experience includes Fortune 500 public company management, M&A, corporate strategy development, risk and compliance, and finance and business shared services programs. She’s held senior leadership positions in various high-tech sectors including PayPal, TIO Networks, SAP, and 360networks, where she led business units and built best-in-class corporate culture.
Amir Javidan – Chief Operations Officer
In his over 15 years of experience as a technology and operations executive, Javidan has been involved in two successful exits. Most recently, he was the SVP of Operations for TIO Networks, overseeing its C$304 million buyout by PayPal. Before that, he was at Avigilon, an integrated cloud and AI-powered solutions company, where he helped scale the business from a “stealth mode” startup to a public company worth over C$1 billion. He also helped take its revenue to over C$100M in five years.
RECAP: 10 Reasons Investors Should Seriously Consider Adding WELL Health Technologies Corp. (TSX: WELL – OTC: WLYYF) to Their Portfolios
It is a multi-channel, multi-product healthtech conglomerate that has the capability to benefit from multiple areas of the industry
A proven track record of accretive acquisitions of profit-generating businesses – all with carefully controlled dilution
Internal synergies from cross-selling can further boost the value of its acquisitions
Rapid acquisition and growth strategy gives it strong potential in a lucrative industry
Significantly undervalued compared to its peers; for example, its peer group trades at 10x to 20x revenue multiples, while WELL trades at 5x EV to Sales multiple.
Planned US IPO listing is widely expected to bring its valuations to a range more in line with its peers
Strong investor base including multi-billionaire Li Ka Shing plus other institutional investors, all of whom have shown willingness to pump in capital to support acquisitions
Proven management team with skin in the game that have executed successful M&As and exits
Multiple business lines within the healthtech industry provides defensiveness plus a hybrid physical-virtual competitive moat
Already a significant player within multiple lucrative business lines (such as EMR and telehealth) but with plenty of room to grow remaining
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for WELL Health Technologies Corp. advertising and digital media from Market Jar Media Inc. There may be 3rd parties who may have shares of WELL Health Technologies Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ does not own any shares of WELL Health Technologies Corp. MIQ will not buy or sell shares of WELL Health Technologies Corp. for a minimum of 72 hours from the publication date on this website (May 5, 2021), but reserve the right to buy and sell, and will buy and sell shares of WELL Health Technologies Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
There are two types of healthcare companies that stand out as the biggest potential winners of 2021: companies that are able to produce a widely used vaccine or treatment for certain virus’, and resilient firms that held tough through the worst of 2020 and can benefit from a gradual return to normalcy.
Healthcare technology, commonly referred to as “healthtech,” refers to the use of technologies developed for the purpose of improving any and all aspects of the healthcare system. From telehealth to robotic-assisted surgery, our guide will walk you through what it is and how it’s being used.
Healthcare technology refers to any IT tools or software designed to boost hospital and administrative productivity, give new insights into medicines and treatments, or improve the overall quality of care provided. Today’s healthcare industry is a $2 trillion behemoth at a crossroads. Currently being weighed down by crushing costs and red tape, the industry is looking for ways to improve in nearly every imaginable area. That’s where healthtech comes in. Tech-infused tools are being integrated into every step of our healthcare experience to counteract two key trouble spots: quality and efficiency.
The way we purchase healthcare is becoming more accessible to a wider group of people through the insurance technology industry, sometimes called “insurtech.” Patient waiting times are declining and hospitals are more efficiently staffed thanks to artificial intelligence and predictive analytics. Even surgical procedures and recovery times are being reduced thanks to ultra-precise robots that assist in surgeries and make some procedures less evasive.
This is a very broad sector that can go in many directions, for more information on this sector please enter your email address in the box provided on this page and we will be more than happy to let you know when more information becomes available.
US Economic Advisers are pushing a massive spending package, with a giant infrastructure plan that should blast copper demand into orbit.
Under the moniker of “Build Back Better”, economic advisers for the current US administration are championing a sweeping $3 trillion package to boost the economy, beginning with a massive infrastructure plan.
Once news of the new planned US spending hit the market, demand for metals rose. There was one critical metal in particular that seriously took off hitting a nearly 10 year high… COPPER.[1]
We believe we’ve identified a company that’s perfectly positioned to capitalize on the days ahead, with a pair of enviable properties in a country about to see a major MINING BOOM.
Emerging copper & gold mining developer Ridgestone Mining Inc. (OTC:RIGMF, TSXV:RMI) is poised for a breakout in TWO of Mexico’s top producing mining districts—including the country’s top producing copper region, Sonora.
Mexico’s mining output has already rebounded above pre-pandemic levels, despite ongoing challenges presented by the global health crisis.[2]
But will it be enough?
There’s a SERIOUS global shortage of copper on the horizon—a gap projected to reach 10 million tons in the next decade.[3]
Goldman Sachs has warned of this historic shortage, stating: “the market now on the cusp of the tightest phase in what we expect to be the largest deficit in a decade.”[4]
Among the top producers of copper in the world is Peru, where their central bank just cut projections, due to COVID-related challenges to production.[5] Neighboring Chile is ramping up what it can, with BHP’s Spence Mine expected to hit peak production later this year.[6]
And don’t think that those massive supplies in Chile and Peru will be headed towards the USA to meet this infrastructure boom. Most of those large, copper-loaded ships are headed for Chinese ports.[7]
It’s beginning to look like North American demand will need to be met by North American supply.
Much more will be expected out of one of the largest copper mines in the world by reserve, Buenavista (aka Cananea) Mine.
Currently the 5th largest copper mine in the world[8], the Buenavista Mine is located in Sonora State. It’s owned and operated by Group Mexico, which trades in the USA under the name Southern Copper Corporation (NYSE:SCCO).
It’s also one of the oldest open-pit mines in North America. The importance of the Buenavista Mine is heightened for Southern Copper, especially because the company recently had to cancel its Tia Maria copper project in southern Peru because of “anti-mining terrorism” in the area.[9]
So the focus back on Mexico appears to be even more warranted than before.
Among the Top 10 producing mines in Mexico, 6 are located within the mining districts of either Chihuahua or Sonora.
Ridgestone Mining Inc. (OTC:RIGMF, TSXV:RMI) has established its properties within both of those districts, they’re surrounded by bigger players that will (as will we) be paying very close attention to their developments in the months to come.
In 2021, Ridgestone Mining Inc. (OTC:RIGMF, TSXV:RMI)is looking to advance both its copper-gold Rebeico project and gold-silver Guadalupe y Calvo projects.
After successfully closing TWO over-subscribed private placements, raising $2.32 million earlier this year, Ridgestone Mining is well capitalized and good to go.
We expect BIG results from a still-very-small company, which is primed for a growth spurt in 2021…
5 Key Highlights Pointing at Ridgestone Miningas a Perfect Mining Opportunity in Mexico
TWO high-grade mining projects located within Mexico’s prolific Sierra Madre gold belt
Exploration-stage Rebeico copper-gold project in Sonora
Resource-stage Guadalupe y Calvo gold-silver project in Chihuahua
Rebeico copper-gold project encompasses 3,459 hectares of private land with numerous artisanal gold and copper workings.
Multiple mineralized zones identified: the Alaska Vein, the New Year Zone, the IP Anomaly, and a number of historic mines including the El Cobre copper mine.
Past exploration highlights include:
Alaska Vein
1.5 metres grading 1.2% copper plus 36.1 g/t gold
1.0 metre grading 5.95% copper plus 17.70 g/t gold
New Year Zone
16.25 metres grading 1.79% copper plus 2.13 g/t gold
Waste Dumps (from surface waste dumps/waste material from mining in the 1960s)
111 samples with an average grade of 0.8% copper plus 2.5 g/t gold
El Cobre Mine (underground mine operated during the 1960s, samples taken from waste material)
Samples grading over 2.4% copper
IP Anomaly
A potential copper-gold porphyry highlighted by a target spanning 1,400 metres by 800 metres
Guadalupe y Calvo (GyC) gold-silver project is located within a mining district with historic production of over 2 million ounces of gold and 28 million ounces of silver.
Mineralization is characterized by low-sulfidation epithermal veins with multiple vein structures identified over a 3km strike.
GyC hosts a historical estimate NI 43-101 Indicated resource of 237,000 oz AuEq at a grade of 3.95 g/t AuEq and Inferred resource of 17,000 oz AuEq.
Resource remains open for expansion along strike and at depth.
Proven management team with a track record of discovery and monetization in Sonora State.
Past successes include:
Sale of the largest moly deposit in Mexico for $195 million
Discovery of three gold deposits and one copper deposit which have become significant mines(two of which are still active in Sonora)
Copper-Gold Asset: Rebeico Project
Rebeico is located 115km east of Hermosillo, a main operations support hub for the Sonora mining district.
Comprised of 16 concessions totaling 3,459 hectares on private land(no ejido), the Rebeico is accessible by highway and a network of all-weather roads.
Infrastructure is great, as there are grid electrical power lines within 6.5 km of the property.
Historic exploration on the property focused on the Alaska Vein and New Year Zone.
Alaska Vein drilling highlights included:
1.2% Cu and 36.1 g/t Au over 1.5 m
2.4% Cu and 8.3 g/t Au over 3.25 m
Including 5.95% Cu and 17.7 g/t Au over 1 m
2.8% Cu and 8.7 g/t Au over 2m
New Year Zone drilling highlights includes:
1.79% Cu and 2.13 g/t Au over 16.25m
0.54% Cu over 29.15 m
On top of the two primary zones are additional prospective signs of copper potential. These include samples from historic mines, and waste by-products.
Waste Dumps (waste material from mining in the 1960’s) data includes:
111 samples with an average grade of 2.5 g/t gold plus 0.8% copper from surface waste dumps (waste material from mining in the 1960’s)
El Cobre Mine (historic mine that operated into the 1960s) data includes:
Waste material grading over 2.4% copper
IP Anomaly:
Potential copper-gold porphyry highlighted by a target spanning 1,400 metres by 800 metres
Case Study 1: Southern Copper’s Buenavista Mine
Roughly 125 miles separate RMI’s Rebeico Project and Southern Copper’s Buenavista mine, which are both along the same trend in the prolific Sonora Mining district.
The Buenavista Mine is the oldest operating copper mine in North America, dating back to 1899.
In 2019, the mine produced 965 million pounds (Mlbs) of copper, which accounted for approximately 44% of the company’s total production for that year. The mine also produces silver and molybdenum as by-products. The contained copper at the mine is estimated to be 22.1Mt.[10]
According to the CFO of Southern Copper Corp., Raul Jacob, the company wants to almost double output by 2028, and possibly become the world’s largest producer.[11]
Jacob stated: “If this [copper] price level holds, we should see announcements of new projects coming in the market.”
It’s important to note that in order for Southern Copper to get there, the company has stated it will look at acquisition opportunities that come along, with asset quality being a top priority.
Given that the Rebeico Project is in the same mining district, and comes with full control given the private ownership of the rights, this could potentially make Ridgestone Mining a serious candidate in the years to come, with a very healthy valuation due to a better price environment.
“We feel comfortable in Latin America and very comfortable and positive about copper,” Jacob added, in an interview with Mining.com.
Between March 2020 and March 2021, shares of Southern Copper Corporation (NYSE:SCCO) has seen its shares rise from $26.57 on March 24, 2020 to a high of $81.53 in February 2021—for a rise of +200% in one year.
Gold-Silver Asset: Guadalupe y Calvo (GyC) Project
Located in the town of Guadalupe y Calvo, in SW Chihuahua State (~300km south of Chihuahua City) with excellent road access and strong local infrastructure.
Comprised of 2,750 hectares of contiguous claims covering numerous historical workings, including the Rosario Mine.
Dating back to the 1930s, the Rosario Mine produced over 2 million ounces of gold, and 28 million ounces of silver.
Due to water-handling capabilities of the time, this historic production was limited… NOT because of the mineralization.
That means, that with today’s technology, it’s game on to get this project back up and running!
Management recognized this, as there are EXCELLENT near-term opportunities for resource growth in place, through additional drilling—Mineralization remains OPEN along strike and at depth.
Already there’s been significant exploration (over 200 drill holes) done in the past by companies that are now part of Goldcorp, Aurico Gold, and Endeavour Silver totaling over 50,000 metres.
Included within those drilling results were 4.1 g/t Au and 281 g/t Ag over 2.5 metres with NUMEROUS targets identified for follow-up exploration.
The Northwest striking Rosario fault complex is the project’s main structural feature, with a total width of the mineralized zone up to 80 metres.
Underground historic mining had widths of high-grade gold-silver mineralization up to 10 metres.
Case Study 2: Coeur Mining’s Palmajero Mine
Ridgestone Mining’s (OTC:RIGMF, TSXV:RMI) y Calvo Project is located near the city of the same name, which is just over 100 miles along trend to the southeast of the Palmajero Mine, owned and operated by Coeur Mining, Inc. (NYSE:CDE).
The property consists of a land position that totals approximately 27,233 hectares.
In 2020, the mine produced 6.3 million ounces of silver and 110,608 ounces of gold.
The Palmarejo silver-gold complex consists of:
the Palmarejo mine and processing facility;
the Guadalupe underground mine, located about 8 kilometers southeast of the Palmarejo mine;
the Independencia underground mine, located approximately 800 meters northeast of the Guadalupe underground mine;
other nearby deposits and exploration targets.
Between March 2020 and March 2021, shares of Coeur Mining, Inc. (NYSE:CDE) has seen its shares rise from $2.88 on March 18, 2020 to a high of $11.14 in February 2021—for a rise of 287% within one year.
Peer Groups in the Mexico Mining World
Ridgestone Mining Inc. (OTC:RIGMF, TSXV:RMI)is surrounded by successful mining operations in both the Chihuahua (GyC) and Sonora (Rebeico) regions.
Together, these regions are both within the Sierra Madre corridor, which has been known for its mineral endowment for a very long time.
This is one of the most mining friendly regions of the country.[12]
In particular, the Sonora region is Mexico’s most active mining region for both copper and gold[13]—Sonora contributes to 82.77% of the country’s copper production.[14]
The output and copper extracted from Sonora, in particular, is considered top notch quality, which is why the demand for this metal in the area is growing on a daily basis.[15]
Beyond the copper production, according to Mexico´s Mining Chamber CAMIMEX, more than half (6) of Mexico´s ten largest operational gold mines are in those two regions.
Company
Symbol
Share PriceToday
Mkt Cap
State/Region
Ridgestone Mining Inc.
OTC:RIGMF TSXV:RMI
$0.165
$12.44M
Chihuahua / Sonora
Fresnillo PLC
OTC:FNLPF
$13.25
$9.63B
Sonora
Southern Copper
NYSE:SCCO
$67.48
$52.17B
Sonora
Starcore International Mines
OTC:SHVLF TSX:SAM
$0.21
$10.1M
Sonora
Minera Frisco
OTC:MSNFY
$0.49
$1.67B
Sonora
Sierra Metals Inc.
NYSE:SMTS TSX:SMT
$3.06
$500M
Chihuahua
Agnico Eagle Mines Limited
NYSE:AEM TSX:AEM
$60.46
$14.66B
Chihuahua
Alamos Gold Inc.
NYSE:AGI TSX:AGI
$8.18
$3.21B
Sonora
First Majestic Silver Corp.
NYSE:AG TSX:FR
$17
$3.77B
Sonora/Durango
Argonaut Gold Inc.
OTC:ARNGF TSX:AR
$1.76
$541.3M
Sonora
As of April 13, 2021, all numbers are approximate.
* All price in USD ** Latest share price taken from Yahoo! Finance on April 13, 2021
Ridgestone Mining’s Management Team
Before it had even acquired its properties, perhaps the #1 asset that Ridgestone Mining had in place was its leadership team. Each member brings a proven track record of discovery and monetization, with expertise specific to Sonora State.
Past successes include the sale of the largest moly deposit in Mexico for $195 million, and the discovery of three gold deposits that have gone on to become significant mines—two of which are still active in Sonora to this day.
Among the talented team, here are some members we felt were necessary to highlight:
CEO & Director – Jonathan George
George is a geologist and mining entrepreneur with over 35 years of experience in exploration, development and financing. Previously President, CEO and co-founder of Creston Moly. Successfully raised $40 million in equity to acquire, develop, and de-risk the El Creston project before selling it to Mercator Minerals for $195 million. Other notable highlights include President and CEO of ESO Uranium, the predecessor to Alpha Minerals which was acquired by Fission Uranium for $185 million.
CFO & Director – Erwin Wong
Wong has over 26 years of experience having served in senior management and board level positions for numerous Chinese and Canadian based enterprises, both public and private, which were involved in various sectors including transport, real estate, mining, life sciences and investment banking. He had also founded a corporate advisory firm which assisted a number of companies with the complexities of initial public offerings, corporate governance and regulatory compliance in various jurisdictions. Erwin Wong is a Chartered Accountant and holds a Bachelor of Commerce from the University of British Columbia.
VP Exploration – Noris Del Bel Belluz
Belluz has over 35 years of experience in operations, exploration, geology and technical evaluations of both underground and open pit mines. Most recently, he was Operations Manager & Acting General Manager for Nevsun Resource’s Bisha mine, which was acquired for $1.8 billion by Zijin Mining Group Co. Previously, he was Manager of Mine Geology for Eldorado Gold’s China operations and with Freeport-McMoRan as Manager of Mine Geology at the Grasberg mine in Indonesia which included a key role in the discovery of the Kucing Liar skarn deposit. Belluz’s technical experience also includes holding senior roles with Stantec Engineering and Wardrop Engineering, overseeing various technical studies from NI 43-101 resource estimates to feasibility studies and detailed engineering. He holds a Bachelor of Science Degree in Geology from the University of Toronto and is a Qualified Person (QP) under NI 43-101.
Advisor – Dr. Andrew J. Ramcharan
Dr. Ramcharan has over 20 years’ experience in operations, project evaluation, mergers and acquisitions, corporate development, project finance and investor relations. Mr. Ramcharan has worked for a number of companies including IAMGOLD Corporation, Sprott Resources and Resource Capital Funds. He holds a Master’s and Ph.D Degree in Mining and Minerals Economics. Andrew is a Registered Member of The Society for Mining, Metallurgy and Exploration (SME) in USA, Licensed Professional Engineer in Ontario, Canada and Fellow of The Australasian Institute of Mining and Metallurgy. A graduate of the Colorado School of Mines, University of Leoben, and Harvard University’s Continuing Education program.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Ridgestone Mining Inc. advertising and digital media from the company directly (“the Company”). There may be 3rd parties who may have shares of Ridgestone Mining Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Ridgestone Mining Inc. which were purchased as a part of a private placement. MIQ will not buy or sell shares of Ridgestone Mining Inc. for a minimum of 72 hours from the publication date on this website March 31, 2021, but reserve the right to buy and sell, and will buy and sell shares of Ridgestone Mining Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Gold gets plenty of attention, but the outlook for base metals like copper is also positive in 2021. RBC Capital Markets analysts raised their 2021 average price estimate from $3.25 to $3.50 a pound due to higher consumption estimates. They expect copper consumption to be higher this year due to indicators that the economy is strengthening.
In a recent report, analyst Sam Crittenden and his team said the backdrop for copper remains positive this year, while low inventories support higher prices. However, they expect the supply response throughout the year to be gradual from both mines and scrap. These factors could moderate the copper price.
Copper equities also remain well-positioned in 2021, and the RBC analysts are starting to see multiple expansion as investors become more interested in the sector.
They note that North American base metals stocks have traded at an average EV/EBITDA multiple of 5.8 times over the last decade. On the other hand, the TSX index trades at a multiple of 9.2 times. Currently, North American base metals stocks are trading at a multiple of 6.9 times, while the TSX is at a multiple of 12 times.
We are following a few promising copper companies, for more information please enter your email in the box provided.
